Browsing by Author "Prasher, P."

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Hybrid molecules based on 1,3,5-triazine as potential therapeutics: A focused review
    (2020) Prasher, P.; Sharma, M.; Aljabali, Alaa A. A.; Gupta, G.; Negi, P.; Kapoor, D. N.; Singh, I.; Zacconi, Flavia C. M.; Andreoli Pinto, T. de J.; Webba da Silva, M.; Bakshi, H.; Chellappan, D. K.; Tambuwala, M. M.; Dua, K.
    Majority of the representative drugs customarily interact with multiple targets manifesting unintended side effects. In addition, drug resistance and over expression of the cellular efflux-pumps render certain classes of drugs ineffective. With only a few innovative formulations in development, it is necessary to identify pharmacophores and novel strategies for creating new drugs. The conjugation of dissimilar pharmacophoric moieties to design hybrid molecules with an attractive therapeutic profile is an emerging paradigm in the contemporary drug development regime. The recent decade witnessed the remarkable biological potential of 1,3,5-triazine framework in the development of various chemotherapeutics. The appending of the 1,3,5-triazine nucleus to biologically relevant moieties has delivered exciting results. The present review focuses on 1,3,5-triazine based hybrid molecules in the development of pharmaceuticals.
  • Thumbnail Image
    Item
    Synthesis and Anticancer Properties of 'azole' based Chemotherapeutics as Emerging Chemical Moieties: A Comprehensive Review
    (2020) Prasher, P.; Sharma, M.; Zacconi, Flavia C. M.; Gupta, G.; Ajabali, Alaa A. A.; Mishra, V.; Tambuwala, M. M.; Kapoor, D. N.; Negi, P.; Andreoli Pinto, Terezinha de Jesús; Singh, I.; Chellappan, D.; Dua, Kamal
    Azole frameworks serve as privileged scaffolds in the contemporary drug design paradigm owing to their unique physicochemical profile that promotes the development of highly selective, physiological benevolent chemotherapeutics. Several azole nuclei function as bioisostere in medicinal chemistry and prompt the development of tailored therapeutics for targeting the desired biological entities. Besides, the azole scaffold forms an integral part in the advanced drug designing methodologies, such as target template insitu drug synthesis, that assists in rapid identification of the hit molecules form a diverse pool of leads; and direct biomolecule-drug conjugation, along with bioorthogonal strategies that ensure localization, and superior target specificity of the directed therapeutic. Lastly, the structural diversity of azole framework and high yielding click synthetic methods provide a comprehensive Structure-Activity Relationship analysis for design optimization of the potential drug molecules by fine-tuning the placement of different substituents critical for the activity. This review provides a comprehensive analysis of the synthesis and anticancer potential of azole based chemotherapeutics.
  • Thumbnail Image
    Item
    Targeting eosinophils in respiratory diseases: biological axis, emerging therapeutics and treatment modalities
    (2021) Lee, L.-Y.; Hew, G.S.Y.; Mehta, M.; Shukla, S.D.; Satija, S.; Khurana, N.; Anand, K.; Dureja, H.; Singh, S.K.; Mishra, V.; Singh, P.K.; Gulati, M.; Prasher, P.; Aljabali, A.A.A.; Tambuwala, M.M.; Thangavelu, L.; Panneerselvam, J.; Gupta, G.; Zacconi, Flavia C. M.; Shastri, M.; Jha, N.K.; Xenaki, D.; MacLoughlin, R.; Oliver, B.G.; Chellappan, D.K.; Dua, K.
    Eosinophils are bi-lobed, multi-functional innate immune cells with diverse cell surface receptors that regulate local immune and inflammatory responses. Several inflammatory and infectious diseases are triggered with their build up in the blood and tissues. The mobilization of eosinophils into the lungs is regulated by a cascade of processes guided by Th2 cytokine generating T-cells. Recruitment of eosinophils essentially leads to a characteristic immune response followed by airway hyperresponsiveness and remodeling, which are hallmarks of chronic respiratory diseases. By analysing the dynamic interactions of eosinophils with their extracellular environment, which also involve signaling molecules and tissues, various therapies have been invented and developed to target respiratory diseases. Having entered clinical testing, several eosinophil targeting therapeutic agents have shown much promise and have further bridged the gap between theory and practice. Moreover, researchers now have a clearer understanding of the roles and mechanisms of eosinophils. These factors have successfully assisted molecular biologists to block specific pathways in the growth, migration and activation of eosinophils. The primary purpose of this review is to provide an overview of the eosinophil biology with a special emphasis on potential pharmacotherapeutic targets. The review also summarizes promising eosinophil-targeting agents, along with their mechanisms and rationale for use, including those in developmental pipeline, in clinical trials, or approved for other respiratory disorders.